Biothera

Biothera Pharmaceuticals Inc. is a mid clinical-stage biotechnology company advancing Imprime PGG, a first-in-class, systemically administered beta glucan PAMP (pathogen associated molecular pattern). Imprime PGG acts as an immunological “ignition switch,” triggering a robust, coordinated immune response to enhance the anti-tumor effects of checkpoint inhibitors (PD-1, PD-L1 antibodies), anti-angiogenic antibodies (e.g., Avastin®), and tumor-targeting monoclonal antibodies (e.g., Erbitux®). Imprime PGG is the most advanced PAMP in immune-oncology, with a strong safety profile in 400+ patients and established proof of concept in single arm and randomized Phase 2 studies in non-small cell lung cancer (NSCLC), colorectal cancer (mCRC), and chronic lymphocytic leukemia (CLL). Imprime PGG has broad intellectual property protections, with more than 100 issued and pending patients in the US and internationally. Biothera Pharmaceuticals is a subsidiary of Biothera Holding Corp., a privately held company.
Type
Private
HQ
Eagan, US
Founded
1997
Employees
81 (est)-2%
Biothera was founded in 1997 and is headquartered in Eagan, US

Key People at Biothera

Steven Karel

Steven Karel

COO
Daniel Conners

Daniel Conners

Founder, President & Chairman
William Gacki

William Gacki

CFO
Myra Patchen

Myra Patchen

CSO
Richard Mueller

Richard Mueller

CEO

Biothera Locations

Eagan, US

Biothera Metrics

Biothera Summary

Founding Date

1997

Total Funding

$5.09 M

Latest funding size

$1.59 M

Time since last funding

almost 2 years
Biothera's latest funding round of $1.59 M was in December 2014. In total, Biothera has raised $5.09 M.
42% of current employees of Biothera are female and 58% are male.

Biothera Company Life

You may also be interested in